Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation

Summary

P-selectin inhibition has been evaluated as a therapeutic for prevention and treatment of venous thrombosis. In this study, a novel oral small-molecule inhibitor of P-selectin, PSI-421, was evaluated in a baboon model of stasis induced deep vein thrombosis (DVT). Experimental groups included i) primates receiving a single oral dose of 1 mg/kg PSI-421 two days prior and continued six days after thrombosis (n=3); ii) primates receiving a single daily subcutaneous dose of 0.57 mg/kg enoxaparin sodium two days prior and continued six days post thrombosis (n=3); and iii) primates receiving no treatment (n=3).PSI-421 treated primates had greater percent vein reopening and less vein wall inflammation than the enoxaparin and controls at day 6. Microparticle tissue factor activity (MPTFA) was significantly lower in the animals receiving PSI-421 immediately after thrombosis (T+6 hours day 0) suggesting lower potential for thrombogenesis in these animals. PSI-421 also reduced soluble P-selectin levels versus controls at T+6 hours day 0, day 2 and 6. Experimental animals in any group showed no adverse effects on coagulation. This study is the first to demonstrate a reduction in MPTFA associated with vein reopening and reduced vein inflammation due to oral P-selectin inhibition in a baboon model of DVT.

Keywords

Venous thrombosis - small-molecule inhibitor of P-selectin - P-selectin - veins - microparticle tissue-factor activity

^* Dr. Thomas R. Meier is currently affiliated with Mayo Clinic, Rochester, MN, USA.

^** Dr. Robert G. Schaub is currently affiliated with the Archemix Corp., Cambridge, MA, USA.

• References

• 1 Heit JA, Cohen AT, Anderson Jr. FA. et al. Estimated annual number of incident and recurrent, nonfatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005; 106 Abstract. 910.
• 2 Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3: 1611-1617.
• 3 Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006; 21: 23-29.
• 4 Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 4: 62-69.
• 5 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
• 6 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Int Med 2000; 160: 761-768.
• 7 Mohr DN, Silverstein MD, Heit JA. et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clinic Rroc 2000; 75: 1249-1256.
• 8 LOVENOX® (enoxaparin sodium injection) Prescribing Information.. Sanofi-Aventis U.S. LLC., Bridgewater; NJ, USA: 2004
• 9 Colwell Jr. CW, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop Rel Res. 1995: 215-222.
• 10 Freedman KB, Brookenthal KR, Fitzgerald Jr. RH. et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg 2000; 82-A: 929-938.
• 11 Colwell Jr. CW, Pulido P, Hardwick ME. et al. Patient compliance with outpatient prophylaxis: an observational study. Orthopedics 2005; 28: 143-147.
• 12 Sharma S. Upper gastrointestinal bleeding after hip and knee arthroplasty. Orthopedics 2006; 29: 255-257.
• 13 Stenberg PE, McEver RP, Shuman MA. et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886.
• 14 Bonfanti R, Furie BC, Furie B. et al. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989; 73: 1109-1112.
• 15 Andre P. P-selectin in haemostasis. Br J Haematol 2004; 126: 298-306.
• 16 Moore KL. Structure and function of P-selectin glycoprotein ligand-1. Leukemia Lymphoma 1998; 29: 1-15.
• 17 Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004; 92: 459-466.
• 18 Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999; 81: 1-7.
• 19 McEver RP, Cummings RD. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100: 485-491.
• 20 Celi A, Lorenzet R, Furie BC. et al. Microparticles and a P-selectin-mediated pathway of blood coagulation. Dis Markers 2004; 20: 347-352.
• 21 Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005; 3: 1590-1596.
• 22 Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10: 171-178.
• 23 Falati S, Liu Q, Gross P. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-1598.
• 24 Bedard PW, Clerin V, Sushkova N. et al. Novel P-selectin inhibitor, PSI-697, demonstrates positive activity following oral administration in rodent models of vascular inflammation. J Thromb Haemost 2005; 3 (Suppl. 01) OR390.
• 25 Kaila N, Janz K, Huang A. et al. 2-(4-Chlorobenzyl)- 3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quino line-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists. J Med Chem 2006; 50: 40-64.
• 26 Kumar A, Villani MP, Patel UK. et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999; 99: 1363-1369.
• 27 Myers Jr. DD, Henke PK, Bedard PW. et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg 2006; 44: 625-632.
• 28 Myers Jr. DD, Wrobleski SK, Londy FJ. et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb Haemost 2002; 87: 374-382.
• 29 Myers Jr. DD, Wrobleski SK, Longo C. et al. Resolution of venous thrombosis using a novel oral smallmolecule inhibitor of P-selectin (PSI-697) without anticoagulation. Thromb Haemost 2007; 97: 400-407.
• 30 Wakefield TW, Strieter RM, Schaub R. et al. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surg 2000; 31: 309-324.
• 31 Wakefield TW, Strieter RM, Wilke CA. et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arteriosclerosis Thromb Vasc Biol 1995; 15: 258-268.
• 32 Kaila N, Janz K, Huang A. et al. 2-(4-Chlorobenzyl)- 3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quino line-4-carbox ylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists. J Med Chem 2007; 50: 40-64.
• 33 Myers Jr. DD, Rectenwald JE, Bedard PW. et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg 2005; 42: 329-336.
• 34 Myers Jr. DD, Wrobleski SK, Henke PK. et al. Coagulation Biology. Surgical Research.. Academic Press; San Diego: 2001
• 35 Hernandez RJ, Strouse PJ, Londy FJ. et al. Gadolinium-enhanced MR angiography (Gd-MRA) of thoracic vasculature in an animal model using double-dose gadolinium and quiet breathing. Ped Radiol 2001; 31: 589-593.
• 36 Myers Jr. DD, Schaub R, Wrobleski SK. et al. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost 2001; 85: 423-429.
• 37 Institute of Laboratory Animal Resources (U.S.). Guide for the care and use of laboratory animals.. [7th ed. National Academy Press; Washington, D.C., USA: 1996
• 38 Kelly CA, Gleiser CA. Selected coagulation reference values for adult and juvenile baboons. Lab Anim Science 1986; 36: 173-175.
• 39 Feingold HM, Pivacek LE, Melaragno AJ. et al. Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood. Am J Vet Res 1986; 47: 2197-2199.
• 40 Physicians' desk reference 2007. 61st Thomson PDR. Montvale, NJ, USA: 2007
• 41 Sanderink GJ, Guimart CG, Ozoux ML. et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-231.
• 42 Jacobs LG, Nutescu E, Smith DA. Thrombosis management: Long-term care perspective. Ann Long-Term Care. 2003 Supplement.
• 43 Sturk-Maquelin KN, Nieuwland R, Romijn FP. et al. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003; 1: 1920-1926.
• 44 Rauch U, Bonderman D, Bohrmann B. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175.
• 45 Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arteriosclerosis Thromb Vasc Biol 2007; 27: 1687-1693.
• 46 Celi A, Pellegrini G, Lorenzet R. et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767-8771.
• 47 Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999; 274: 23111-23118.